Parametric Portfolio Associates LLC Acquires 7,187 Shares of Albany Molecular Research, Inc. (AMRI)

Parametric Portfolio Associates LLC lifted its holdings in shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) by 24.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,527 shares of the biotechnology company’s stock after buying an additional 7,187 shares during the period. Parametric Portfolio Associates LLC owned about 0.09% of Albany Molecular Research worth $793,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Arizona State Retirement System boosted its stake in shares of Albany Molecular Research by 0.9% during the 2nd quarter. Arizona State Retirement System now owns 11,686 shares of the biotechnology company’s stock worth $254,000 after buying an additional 100 shares during the last quarter. Texas Permanent School Fund boosted its stake in shares of Albany Molecular Research by 0.9% during the 2nd quarter. Texas Permanent School Fund now owns 16,299 shares of the biotechnology company’s stock worth $354,000 after buying an additional 151 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of Albany Molecular Research by 5.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 5,260 shares of the biotechnology company’s stock worth $114,000 after buying an additional 290 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Albany Molecular Research by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 101,876 shares of the biotechnology company’s stock worth $2,211,000 after buying an additional 589 shares during the last quarter. Finally, Thrivent Financial For Lutherans boosted its stake in shares of Albany Molecular Research by 5.4% during the 1st quarter. Thrivent Financial For Lutherans now owns 12,640 shares of the biotechnology company’s stock worth $177,000 after buying an additional 650 shares during the last quarter. Institutional investors own 72.10% of the company’s stock.

Albany Molecular Research, Inc. (NASDAQ AMRI) opened at $21.74 on Tuesday. Albany Molecular Research, Inc. has a one year low of $13.01 and a one year high of $22.17. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.37 and a current ratio of 0.68.

ILLEGAL ACTIVITY WARNING: “Parametric Portfolio Associates LLC Acquires 7,187 Shares of Albany Molecular Research, Inc. (AMRI)” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://sportsperspectives.com/2017/11/21/parametric-portfolio-associates-llc-acquires-7187-shares-of-albany-molecular-research-inc-amri.html.

Separately, BidaskClub upgraded shares of Albany Molecular Research from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Five investment analysts have rated the stock with a hold rating, The company presently has a consensus rating of “Hold” and a consensus price target of $18.00.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply